Overview
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Basic Stats
The share price of ChemoCentryx Inc as of October 19, 2022 is $51.99 / share.
The Factor Analysis chart (below right) shows a view of ChemoCentryx Inc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for ChemoCentryx Inc is $53.04. The forecasts range from a low of $52.52 to a high of $54.60. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
| Record Date | Projection Date | High | Low | Median | Average |
|---|---|---|---|---|---|
| 2023-03-27 | 2024-03-27 | 54.60 | 52.52 | 53.04 | 53.04 |
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for ChemoCentryx Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-08-10 | Stifel | Buy | Hold | Downgrade |
| 2022-08-05 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2022-08-05 | Raymond James | Strong Buy | Market Perform | Downgrade |
| 2022-08-05 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2022-08-05 | Canaccord Genuity | Buy | Hold | Downgrade |
| 2022-05-06 | Raymond James | Strong Buy | Maintains | |
| 2021-11-10 | Raymond James | Strong Buy | Maintains | |
| 2021-10-11 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2021-10-11 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2021-10-11 | JP Morgan | Underweight | Neutral | Upgrade |
| 2021-10-08 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2021-07-07 | Stifel | Hold | Buy | Upgrade |
| 2021-05-07 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2021-05-07 | Stifel | Buy | Hold | Downgrade |
| 2021-05-07 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2021-05-07 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2021-05-07 | JP Morgan | Neutral | Underweight | Downgrade |
| 2021-05-07 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-03-02 | Stifel | Buy | Initiate | |
| 2021-03-02 | Raymond James | Strong Buy | Maintains | |
| 2021-01-08 | Raymond James | Strong Buy | Maintains | |
| 2020-10-29 | Wells Fargo | Overweight | Maintains | |
| 2020-10-29 | SVB Leerink | Outperform | Maintains | |
| 2020-10-29 | Piper Sandler | Overweight | Maintains | |
| 2020-10-29 | JP Morgan | Overweight | Neutral | Downgrade |
| 2020-08-11 | Raymond James | Strong Buy | Maintains | |
| 2020-07-29 | JP Morgan | Overweight | Maintains | |
| 2020-06-17 | BTIG | Buy | Initiate | |
| 2020-05-27 | Wells Fargo | Overweight | Initiate | |
| 2020-05-19 | Canaccord Genuity | Buy | Maintains | |
| 2020-05-14 | JP Morgan | Overweight | Maintains | |
| 2020-05-12 | SVB Leerink | Outperform | Reiterate | |
| 2020-05-12 | Raymond James | Strong Buy | Reiterate | |
| 2020-05-12 | Canaccord Genuity | Buy | Maintains | |
| 2020-03-11 | Raymond James | Strong Buy | Maintains | |
| 2020-03-11 | JP Morgan | Overweight | Maintains | |
| 2020-02-18 | JP Morgan | Overweight | Maintains | |
| 2020-01-24 | H.C. Wainwright | Buy | Maintains | |
| 2019-11-26 | Raymond James | Strong Buy | Maintains | |
| 2019-11-26 | Canaccord Genuity | Buy | Maintains | |
| 2019-09-12 | JP Morgan | Neutral | Overweight | Upgrade |
| 2019-06-06 | Raymond James | Strong Buy | Maintains | |
| 2019-03-27 | B. Riley FBR | Neutral | Buy | Upgrade |
| 2019-02-11 | PiperJaffray | Overweight | Initiate | |
| 2018-11-12 | Canaccord Genuity | Buy | Buy | Maintains |
| 2018-09-07 | B. Riley FBR | Neutral | Initiate | |
| 2018-08-14 | JP Morgan | Overweight | Neutral | Downgrade |
| 2018-06-28 | Raymond James | Strong Buy | Initiate | |
| 2018-05-16 | Canaccord Genuity | Buy | Initiate | |
| 2018-05-02 | H.C. Wainwright | Buy | Initiate | |
| 2018-03-13 | JP Morgan | Overweight | Overweight | Maintains |
| 2015-05-18 | JP Morgan | Neutral | Overweight | Upgrade |
| 2013-12-04 | Citigroup | Buy | Neutral | Downgrade |
| 2013-09-10 | JP Morgan | Overweight | Neutral | Downgrade |
| 2013-05-20 | Stifel Nicolaus | Buy | Maintains | |
| 2012-11-14 | Stifel Nicolaus | Buy | Initiate | |
| 2012-03-19 | JP Morgan | Overweight | Initiate |
